JOURNAL OF INTEGRATED OMICS
A METHODOLOGICAL JOURNAL
HTTP://WWW.JIOMICS.COM

EDITORIAL | DOI: 10.5584/jiomics.v15i2.246

# Overcoming Barriers to Personalized Medicine

José L. Capelo[1,2,*], Carlos Lodeiro[1,2] , Laura Mercolini[3] , Michele Protti[3] , Roberto Mandrioli[4] , Ivana Pibiri[5] , Marco Tutone[5] , Federica Pellati[6] , Gianluca Moroncini[7] , Rossella De Marco[8] , Daphné Chopard[9] , Lena Voith von Voithenberg[10] , Nir Peled[11] , Michael Y. Sherman[12] , Mor Moskovitz[13] , Tian-Li Wang[14] , Rong Fan[15] , Gamze Gürsoy[16,17] , Varum Kumar Nomula[18] , Tânia S. Morais[19,20] , Francisco J. López Hernández[21] , Daniele Lo Re[22] , Stavroula Baritaki[23] , Anna Bielecka Wajdman[24] , Cristina Zibetti[25] , Erica Quagliarini[26] , Manuela Iacobini[27] , Sobia Noreen[3] , Luís Perpétuo[28,29] , Leandro Teodoro Júnior[30,31]

[1](Bio)Chemistry & Omics, BIOSCOPE Research Group, LAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, NOVA University of Lisbon, 2829-516 Caparica, Portugal. [2]PROTEOMASS Scientific Society, Praceta Jerónimo Dias, 2825-466 Costa da Caparica, Portugal. [3]Pharmaco-Toxicological Analysis (PTA Lab), Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126, Bologna, Italy. [4]Department for Life Quality Studies, Alma Mater Studiorum - University of Bologna, Corso d'Augusto 237, 47921 Rimini, Italy. [5]Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), University of Palermo, 90123 Palermo, Italy. [6]Department of Life Sciences, University of Modena and Reggio Emilia, Via G. Campi 103, 41125 Modena, Italy. [7]Clinica Medica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, 60126 Ancona, Italy. [8]Department of Agricultural, Food, Enviromental and Animal Sciences (Di4A), University of Udine, via Cotonificio 108, Udine, 33100, Italy. [9]School of Computer Science and Informatics, Cardiff University, 5 The Parade, Cardiff, CF24 3AA, UK. [10]Department of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany. [11]The Helmsley Cancer Center, The Hebrew University of Jerusalem, Shaare Zedek Medical Center Shmuel Beit 12, Jerusalem, Israel. [12]Department of Molecular Biology, Ariel University, Israel. [13]Davidoff Cancer Center, Beilinson MC, Petah Tikva, Israel. [14]Department of Pathology, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA. [15]Department of Biomedical Engineering, Yale University, New Haven, CT 06520, USA. [16]Department of Biomedical Informatics, Columbia University, New York, NY, USA. [17]New York Genome Center, New York, NY, USA. [18]Apex ITS LLC, New Jersey, United States. [19]Centre for Structural Chemistry, Institute of Molecular Sciences, Lisbon, Portugal. [20]Department of Chemical Engineering, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisbon, Portugal. [21]Instituto de Investigación Biomédica de Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain. [22]Department of Medicinal and Organic Chemistry, Faculty of Pharmacy, University of Granada, Spain. [23]Experimental Oncology Research Lab, School of Medicine, University of Crete, Voutes campus, 70013, Greece. [24]Department of Pharmacology, Medical University of Silesia, 40-752 Katowice, Poland. [25]Independent researcher. [26]Department of Molecular Medicine, Sapienza University of Rome, Italy. [27]Department of Anatomy, Histology, Forensic Medicine and Orthopaedics, Sapienza University of Rome, Italy. [28]iBiMED, Department of Medical Sciences, University of Aveiro. [29]RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto. [30]Cell and Molecular Therapy NUCEL Group, School of Medicine, University of São Paulo, São Paulo 01246-903, Brazil. [31]Biochemistry Department, Chemistry Institute, University of São Paulo, São Paulo 05508-900, Brazil.

**Available Online**: June 2025

In the last few decades, medicine has undergone transformative changes driven by advancements in omics technologies - genomics, proteomics, metabolomics, and transcriptomics. These innovations have provided unprecedented insights into the molecular underpinnings of human health and disease, offering the potential to revolutionize the way we diagnose, treat, and prevent illnesses. However, the current regulatory framework governing clinical assays remains rooted in outdated models that do not fully accommodate the possibilities offered by personalized medicine. This manifesto advocates for a fundamental shift in the regulation of clinical assays, proposing the integration of omics technologies to enable physicians to implement personalized medicine effectively.

Personalized medicine is not just a future vision; it is an emerging reality that is transforming patient care. By tailoring medical treatment to the individual characteristics of each patient, based on their genetic makeup, protein expression profiles, metabolic states, and gene expression patterns, personalized medicine promises to enhance treatment efficacy, reduce adverse drug reactions, and ultimately improve patient outcomes [1,2]. Genomics provides the blueprint of life, offering insights into genetic predispositions to diseases, drug responses, and potential therapeutic targets [3]. Proteomics examines the dynamic expression of proteins, the cellular workhorses that are crucial for understanding disease mechanisms and identifying biomarkers for early diagnosis and targeted therapy [4,5]. Metabolomics captures the end products of cellular processes, reflecting the metabolic state of a patient, which is essential for understanding complex diseases such as cancer, diabetes, and cardiovascular diseases [6,7]. Transcriptomics analyzes RNA transcripts to understand gene expression patterns, revealing how genes are turned on or off in different tissues and under various conditions, which is vital for identifying disease mechanisms and potential therapeutic targets [8]. These omics technologies offer a comprehensive view of a patient's health, far surpassing the capabilities of traditional diagnostic methods. Therefore, integrating these into clinical practice is not merely an

***Corresponding author:** José L. Capelo | email: jlcapelom@bioscopegroup.org

enhancement but a necessity for modern healthcare. To fully realize these benefits, integrating existing biochemical and proteomic methods with next-generation sequencing will be essential to validate the identified factors and related regulatory substrates for patient-tailored, autologous transplantation therapies [9,10].

The current regulatory environment for clinical assays is based on principles developed for a one-size-fits-all approach to medicine. Traditional clinical trials, which form the backbone of regulatory approval processes, are designed around large, homogeneous populations. These trials aim to establish the efficacy and safety of treatments across broad patient groups but often fail to account for the genetic and molecular diversity among individuals [11,12]. This one-size-fits-all approach prioritizes population-level outcomes, often overlooking the variations in drug responses that occur due to genetic differences, leading to treatments that may be effective for some but not for others [13]. Despite significant advancements in omics, current regulations have been slow to incorporate these technologies into the clinical trial framework, hampering the development and approval of personalized therapies that could significantly improve patient outcomes [1]. The existing regulatory framework imposes substantial barriers to the integration of personalized medicine into clinical practice, including lengthy approval processes, stringent requirements for large-scale trials, and a focus on broad applicability over individual effectiveness [14].

To harness the full potential of personalized medicine, we must overhaul the current regulatory framework to accommodate the unique characteristics of omics-based approaches. This reform should be guided by several key principles. Firstly, the new regulatory framework should prioritize the recognition of individual variability in drug responses. This involves shifting from population-based to individual-based assessments, where the efficacy and safety of treatments are evaluated based on genetic, proteomic, metabolomic, and transcriptomic profiles [1]. Secondly, we must move towards adaptive clinical trial designs that allow for continuous learning and real-time modifications based on patient responses. This approach will enable the integration of omics data into the trial process, ensuring that treatments are tailored to the unique characteristics of each patient [15]. Thirdly, regulatory bodies should implement expedited approval pathways for therapies that demonstrate significant potential based on omics data, recognizing the validity of surrogate endpoints identified through these technologies, and allowing for conditional approvals that can be refined as more data becomes available [16].

Additionally, the regulatory reform should encourage interdisciplinary collaboration between clinicians, researchers, regulatory bodies, and industry. This collaboration is essential for developing robust frameworks that integrate omics technologies into clinical practice while ensuring patient safety and treatment efficacy [1,17]. Moreover, in addition to traditional clinical trial data, the new regulatory framework should incorporate real-world evidence (RWE) from clinical practice. RWE can provide valuable insights into how treatments perform in diverse patient populations and under real-world conditions, offering a more comprehensive understanding of treatment effectiveness [18,19].

The potential of personalized medicine, driven by advances in omics technologies, is immense. However, realizing this potential requires a fundamental shift in the regulatory framework governing clinical assays. By embracing a model that recognizes individual variability, supports adaptive trial designs, expedites the approval of omics-based therapies, and integrates real-world evidence, we can ensure that personalized medicine becomes the standard of care. This manifesto calls on policymakers, regulatory bodies, and the medical community to take bold steps towards reforming clinical assay regulations. The future of medicine lies in our ability to treat each patient as a unique individual, informed by the wealth of data provided by genomics, proteomics, metabolomics, and transcriptomics. It is time to break free from the constraints of outdated regulatory practices and pave the way for a new era of personalized healthcare.

**Conflict of Interest**

Lena von Voithenberg is an employee of F. Hoffmann-La Roche.

**References**

[1] G. Molla and M. Bitew, "Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives," Biomedicines, vol. 12, no. 12, p. 2750, Nov. 2024, doi: 10.3390/biomedicines12122750.

[2] G. S. Ginsburg and H. F. Willard, "Genomic and personalized medicine: foundations and applications," Translational Research, vol. 154, no. 6, pp. 277–287, Dec. 2009, doi: 10.1016/j.trsl.2009.09.005.

[3] National Human Genome Research Institute, "Human Genome Project - The most important biomedical research undertaking of the 20th Century," https://www.genome.gov/about-genomics/educational-resources/fact-sheets/human-genome-project.

[4] S. Al-Amrani, Z. Al-Jabri, A. Al-Zaabi, J. Alshekaili, and M. Al-Khabori, "Proteomics: Concepts and applications in human medicine.," World J Biol Chem, vol. 12, no. 5, pp. 57–69, Sep. 2021, doi: 10.4331/wjbc.v12.i5.57.

[5] H. Rodriguez, J. C. Zenklusen, L. M. Staudt, J. H. Doroshow, and D. R. Lowy, "The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment," Cell, vol. 184, no. 7, pp. 1661–1670, Apr. 2021, doi: 10.1016/j.cell.2021.02.055.

[6] J. K. Nicholson and J. C. Lindon, "Metabonomics," Nature, vol. 455, no. 7216, pp. 1054–1056, Oct. 2008, doi: 10.1038/4551054a.

[7] V. Gonzalez-Covarrubias, E. Martínez-Martínez, and L. del Bosque-Plata, "The Potential of Metabolomics in Biomedical Applications," Metabolites, vol. 12, no. 2, p. 194, Feb. 2022, doi: 10.3390/metabo12020194.

[8] R. Lowe, N. Shirley, M. Bleackley, S. Dolan, and T. Shafee, "Transcriptomics technologies," PLoS Comput Biol, vol. 13, no. 5,

p. e1005457, May 2017, doi: 10.1371/journal.pcbi.1005457.

[9] G. Pais et al., "ISAnalytics enables longitudinal and high-throughput clonal tracking studies in hematopoietic stem cell gene therapy applications", Briefings in Bioinformatics, Volume 24, Issue 1, January 2023, bbac551, https://doi.org/10.1093/bib/bbac551

[10] Li, Y., Levine, J., Hakonarson, H. et al. Making the genomic leap in HCT: application of second-generation sequencing to clinical advances in hematopoietic cell transplantation. Eur J Hum Genet 22, 715–723 (2014). https://doi.org/10.1038/ejhg.2013.247

[11] M. A. Hamburg and F. S. Collins, "The Path to Personalized Medicine," New England Journal of Medicine, vol. 363, no. 4, pp. 301–304, Jul. 2010, doi: 10.1056/NEJMp1006304.

[12] M.-W. An, Q. Duong, J. Le-Rademacher, and S. J. Mandrekar, "Principles of Good Clinical Trial Design," Journal of Thoracic Oncology, vol. 15, no. 8, pp. 1277–1280, Aug. 2020, doi: 10.1016/j.jtho.2020.05.005.

[13] L. Marques et al., "Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare.," Pharmaceutics, vol. 16, no. 3, Feb. 2024, doi: 10.3390/pharmaceutics16030332.

[14] D. Stefanicka-Wojtas and D. Kurpas, "Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions)," J Pers Med, vol. 13, no. 3, p. 380, Feb. 2023, doi: 10.3390/jpm13030380.

[15] A. M. Kaizer et al., "Recent innovations in adaptive trial designs: A review of design opportunities in translational research," J Clin Transl Sci, vol. 7, no. 1, p. e125, Apr. 2023, doi: 10.1017/cts.2023.537.

[16] R. Sharma, A. Gulati, and K. Chopra, "Era of surrogate endpoints and accelerated approvals: a comprehensive review on applicability, uncertainties, and challenges from regulatory, payer, and patient perspectives," Eur J Clin Pharmacol, vol. 81, no. 5, pp. 605–623, May 2025, doi: 10.1007/s00228-025-03822-w.

[17] P. Venturini, P. L. Faria, and J. V. Cordeiro, "AI and omics technologies in biobanking: Applications and challenges for public health," Public Health, vol. 243, p. 105726, Jun. 2025, doi: 10.1016/j.puhe.2025.105726.

[18] R. E. Sherman et al., "Real-World Evidence — What Is It and What Can It Tell Us?," New England Journal of Medicine, vol. 375, no. 23, pp. 2293–2297, Dec. 2016, doi: 10.1056/NEJMsb1609216.

[19] K. Verkerk and E. E. Voest, "Generating and using real-world data: A worthwhile uphill battle," Cell, vol. 187, no. 7, pp. 1636–1650, Mar. 2024, doi: 10.1016/j.cell.2024.02.012.